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Finding new treatments targeting cancer stem cells (CSCs) within a tumor seems to be critical to halt cancer and improve patient survival.
Osteosarcoma is an aggressive tumor affecting adolescents, for which there is no second-line chemotherapy. Uncovering newmolecular
mechanisms underlying the development of osteosarcoma and origin of CSCs is crucial to identify new possible therapeutic strategies.
Here, we aimed to characterize genetically and molecularly the human osteosarcoma 3AB-OS CSC line, previously selected fromMG63
cells andwhich proved to have both in vitro and in vivo features of CSCs. Classic cytogenetic studies demonstrated that 3AB-OS cells have
hypertriploid karyotypewith 71–82 chromosomes. By comparing 3AB-OSCSCs to the parental cells, array CGH, Affymetrixmicroarray,
and TaqMan1 Human MicroRNA array analyses identiﬁed 49 copy number variations (CNV), 3,512 dysregulated genes and 189
differentially expressed miRNAs. Some of the chromosomal abnormalities and mRNA/miRNA expression proﬁles appeared to be
congruent with those reported in human osteosarcomas. Bioinformatic analyses selected 196 genes and 46 anticorrelated miRNAs
involved in carcinogenesis and stemness. For the ﬁrst time, a predictive network is also described for two miRNA family (let-7/98 and
miR-29a,b,c) and their anticorrelated mRNAs (MSTN, CCND2, Lin28B, MEST, HMGA2, and GHR), which may represent new
biomarkers for osteosarcoma and may pave the way for the identiﬁcation of new potential therapeutic targets.
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Osteosarcoma, the most common of primary bone
malignancies, is a highly aggressive tumor exhibiting clinical,
histologic, and molecular heterogeneity (Tang et al., 2008).
Classic cytogenetic studies and array CGH analysis in pediatric
and adult osteosarcoma patients have demonstrated that
the majority of osteosarcomas are characterized by complex
chromosomal abnormalities, with specimens varying from
haploid to near-hexaploid, and frequent chromosomal gains
and losses, indicating the highly unstable nature of the
osteosarcoma cell genome (Bridge et al., 1997; Batanian et al.,
2002;Niini et al., 2011). The tumor, which in about 80%of cases
occurs at sites of rapid bone growth (e.g., the metaphyses of
long bones), has an initial peak incidence in the pediatric and
early adult population and a second peak incidence in later adult
life (Tang et al., 2008). The current standard chemotherapy
regimen, which includes cisplatin, doxorubicin, and
methotrexate, provides only 65–70% long-term disease-free
survival for osteosarcoma patients without metastasis (Chou
and Gorlick, 2006), and there is no established second-line
chemotherapy for relapsed osteosarcoma. Thus, there is an
urgent need to identify new therapeutic strategies to improve
the clinical outcome of patients with osteosarcoma.
Currently, a fundamental problem in cancer research is the
identiﬁcation of the cancer stem cells (CSCs) within a cancer
cell population that maintain the malignant potential and
determine resistance to therapy (Clarke et al., 2006). Whether
CSCs derive from transformed stem cells or result from cancer
cells during their progressive development is still an open
question (Bapat, 2007). However, CSCs have been isolated
from a great number of tumors (Visvader and Lindeman, 2008),
and several lines of evidence suggest that tumors contain a small
fraction of cells (CSCs) responsible for the initiation, growth,
and development of the tumor (Giordano et al., 2007). The
discovery of CSCs has changed the role of chemotherapy.
Indeed, most tumors recur after apparently successful
eradication, likely because CSCs survive and restore tumor
growth (Dean et al., 2005); thus, cancer could be caused
by CSCs and the treatment of cancer should require their
eradication. Importantly, although a number of reports have
identiﬁed and characterized CSCs in human osteosarcomas
(Wang et al., 2009, 2011; Rainusso et al., 2011; Tirino et al.,
2011; Martins-Neves et al., 2012), to our knowledge, no human
osteosarcoma CSC line has been developed. In addition, the
genetic andmolecular characterization of human osteosarcoma
CSCs has been little explored.
Cancer is considered to be a disease with multiple genetic/
epigenetic changes that lead to chromosomal instability and
tumor progression (Lagasse, 2008). Although it has been shown
that most cancers are characterized by complex chromosomal
rearrangements associated with copy number aberrations
(Roschke and Kirsch, 2010), there is still debate whether
chromosomal aberrations are essential for cancer initiation or
are an outcome of the tumorigenic process.
We have previously demonstrated that brief treatment
(24–72 h) of human osteosarcoma MG63 cells with 3-
aminobenzamide (3AB), a potent competitive inhibitor of
poly(ADP-ribose) polymerase, markedly reduced their growth
rate, promoting osteocyte differentiation (De Blasio et al.,
2003). This was accompanied by a reprogramming of gene
expression with down-regulation of genes required for
proliferation and up-regulation of those implicated in
osteoblastic differentiation (De Blasio et al., 2005). However,
prolonged treatment of MG63 cells with 3AB (about 100 days)
induced osteocyte death accompanied by a progressive
enrichment of a new cell population. These cells, termed 3AB-
OS, are a heterogeneous and stable cell population, which after
3AB withdrawal and serial passages (currently, more than 200)
has retained its morphological and antigenic features. 3AB-OS
cells show various features of CSCs, including unlimited
proliferative potential, an ATP-binding cassette transporter
ABCG2-dependent phenotype with high drug efﬂux capacity,
and a strong expression of a large number of genes required for
maintaining stemness and for inhibiting apoptosis (Di Fiore
et al., 2009). 3AB-OS cells are highly tumorigenic and
recapitulate in vivo (xenografted athymicmice) various features
of human osteosarcoma, thereby representing a useful model
system to test in vivo novel antitumor approaches against
human osteosarcoma (Di Fiore et al., 2012). They grow in
ultralow-attachment plates at a low density with a high sphere-
formation efﬁciency (Di Fiore et al., 2009), and they penetrate
Matrigel with 2.6-fold higher invasion ability than the parental
MG63 cells. They efﬁciently transdifferentiate, in vitro, into cells
of all three primary germ layers (ectoderm, endoderm, and
mesoderm) which demonstrate various functional properties
(manuscript in preparation).Overall, these results demonstrate
that for the ﬁrst time we have isolated a human osteosarcoma
cancer stem cell line (3AB-OS).
microRNAs (miRNAs) are a large family of non-coding small
RNAs of approximately 22 nucleotides that act primarily by
targeting mRNAs for cleavage or translational repression
(Bartel, 2009). Bioinformatics analyses suggest that up to 30%of
human genes are under the control of miRNAs (Iorio and
Croce, 2009). miRNAs are important regulators of
development and differentiation, and their aberrant expression
can lead to cancer or contribute to determine the stemness
phenotype (Lu et al., 2005; Iorio andCroce, 2009). Although the
role of miRNAs in osteosarcomagenesis is largely unexplored,
some studies have recently describedmiRNA in osteosarcoma,
identifying miRNA signatures associated with the pathogenesis
and progression of osteosarcoma and revealing complex
mechanisms of miRNA deregulation (Maire et al., 2011; Jones
et al., 2012; Kobayashi et al., 2012).
Our study aimed to characterize the 3AB-OS CSC line at
the genetic and molecular level, to identify the molecular
mechanisms likely to give rise and maintain CSCs in
osteosarcoma. This will permit us to identify new potential
therapeutic targets for tailored therapies to eradicate CSCs in
osteosarcoma.
Materials and Methods
Cell cultures
Human osteosarcoma MG63 cells and human ﬁbroblast HS68 cells
were acquired from Interlab Cell Line Collection (ICLC, Genova,
Italy) and American Type Culture Collection (LGC Standards,
Sesto San Giovanni (MI), Italy), respectively. The human 3AB-OS
cells have been produced in our laboratory (Di Fiore et al., 2009)
and patented (Pluripotent CSCs: their preparation and use. N.
Patent Appln. No. FI2008A000238, December 11, 2008). Cell lines
were cultured as monolayers in T-75 ﬂask in Dulbecco’s modiﬁed
Eagle medium (DMEM), supplemented with 10% (v/v) heat-
inactivated fetal bovine serum, 2mM L-glutamine, and antibiotics
(50U/ml penicillin–50mg/ml streptomycin; Euroclone, Pero (MI),
Italy) in a humidiﬁed atmosphere of 5% CO2 in air at 378C.
The culture medium was changed every 3 days. When cells grew
to approximately 80% conﬂuence, they were subcultured or
harvested using 0.025% trypsin-EDTA (Life Technologies Ltd.,
Monza, Italy). Cell viability was tested by trypan blue exclusion.
Karyotype analysis
Karyotype analysis of 3AB-OS cells was performed by Toma
Advanced Biomedical Assays S.p.A. (Busto Arsizio (VA), Italy)
by standard cytogenetic techniques with QFQ banding using
quinacrinemustard (haploid karyotype of 400-band level). Twenty-
two metaphase spreads were analyzed. Clonal chromosomal
abnormalities were described according to the International
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System for Human Cytogenetic Nomenclature (ISCN, 2009;
Brothman et al., 2009).
Propidium iodide staining for DNA ploidy analysis
Trypsinized cell suspensions were centrifuged, washed three times
with phosphate-buffered saline (PBS) and resuspended at
1 106 cells/ml in PBS. Cells were mixed with cold absolute
ethanol and stored for 1 h at 48C. After centrifugation, cells were
rinsed three times in PBS and the pellet was suspended in 1ml of
propidium iodide staining solution (3.8mM sodium citrate, 25mg/
ml PI, 10mg/ml RNase A; Sigma–Aldrich Srl, Milano, Italy) and kept
in the dark at 48C for 3 h prior to ﬂow cytometry analysis. Normal
human lymphocytes were used as a diploid control.
Flow cytometry analysis
Samples were run on a COULTER EPICS XL ﬂow cytometer
(Beckman Coulter Srl, Cassina De Pecchi (MI), Italy) equipped with
a single argon ion laser (emission wavelength of 488 nm) and Expo
32 software. The red ﬂuorescence of the propidium iodide-stained
DNAwas measured in the FL3 channel using a 620 nm BP ﬁlter. At
least 1 104 cells/sample were analyzed and data were stored in
list mode ﬁles. Samples were classiﬁed according to DNA index
range as described by Bauer (1988).
Array CGH analysis
Array-based comparative genomic hybridization (array CGH)
analysis was performed, as reported for karyotype analysis, by
Toma Laboratories. The analysis was comparatively performed on
DNA extracted from 3AB-OS and MG63 cells. A genome-wide
BAC platform (the ConstitutionalChip 4.0, PerkinElmer LAS,
Wallac, Turku, Finland) with an average resolution of 0.6Mb was
used. Genomic DNAwas extracted by the QIAamp DNAMini Kit
(Qiagen, Chatsworth, CA) following the manufacturer’s
instructions. Dye swap labeling, hybridization, and washing steps
were carried out using the supplied kits and following the
manufacturer’s instructions. Hybridization spots were acquired by
an Innoscan 700Microarray Scanner (Innopsys, Carbonne, France)
and analyzed with OneClick software v 4.2.3, which summarizes
results in graphical and tabular formats organized by chromosome
location.Unbalanced aberrationwasmeasured by the average ratio
values, which indicate losses for ratio values<0.7 and gains for ratio
values >1.3. The analytical method applied was the robust binary
segmentation (P-value: 0.001; min clones: 5; min Mbp: 0.1;
threshold: 0.1). Molecular and conventional karyotypes were
described according to the ISCN2009 guidelines (Brothman et al.,
2009).
Centrosome immunostaining, analysis of atypical mitotic
ﬁgures, and nuclei number
MG63, 3AB-OS cells, and HS68 (control ﬁbroblasts) were grown
in six-well plates for 2 days, washed with PBS, ﬁxed with 3.7%
formaldehyde and permeabilized with 0.1% Triton X-100
(Sigma–Aldrich Srl) in PBS.
All antibodies were diluted in PBSþ 1% BSAþ 0.05% NaN3
(Sigma–Aldrich). For centrosome analysis, asynchronously grown
cells were incubated overnight at 48C with a rabbit monoclonal
antibody against g-tubulin (diluted 1:2,000; Sigma–Aldrich Srl). The
cells were then washed in PBS and exposed to Cy2-conjugated
donkey anti-rabbit IgG (Hþ L) secondary antibody (diluted 1:100;
Jackson ImmunoResearch Laboratories, West Grove, PA) for 1 h
at room temperature.
For mitotic spindle analysis, cells were incubated overnight at
48C with a rabbit monoclonal antibody against g-tubulin (diluted
1:2,000) and a mouse monoclonal antibody against b-tubulin
(diluted 1:100; Sigma–Aldrich Srl). The cells were then washed in
PBS and exposed for 1 h at room temperature to Cy2-conjugated
donkey anti-rabbit IgG (Hþ L) secondary antibody and
Cy3-conjugated donkey anti-mouse IgG (Hþ L) secondary
antibody (diluted 1:100; Jackson ImmunoResearch Laboratories).
Nuclei were visualized after staining with DAPI (40,6-diamidino-
2-phenylindole; Sigma–Aldrich Srl) at a concentration of 1mg/ml
in PBS at room temperature for 10min.
Samples were examined on a Leica DM IRB inverted
microscope (Leica Microsystems Srl, Milano, Italy) equipped with
epiﬂuorescence optics and suitable ﬁlters for DAPI, FITC, and
rhodamine detection; Images were photographed and captured by
a computer-imaging system (Leica DC300F camera and Adobe
Photoshop for image analysis).
The percentage of cells with abnormal centrosome number
(>2) was evaluated in 100 isolated (non-overlapping) cells. The
percentage of multipolar mitotic cells (3) was evaluated in 100
cells undergoing mitosis. The percentage of bi- and multinucleated
cells was evaluated in 1,000 isolated (non-overlapping) cells. Four
independent experiments, each conducted in triplicate, were
performed for centrosome, mitotic spindle, and nucleus analyses.
Microarray analysis
Microarray analysis was performed as previously described
(Federico et al., 2010). The analysis was comparatively performed
on total RNAextracted fromMG63 and3AB-OS cells following the
manufacturer’s protocol (Affymetrix, Santa Clara, CA).
Hybridization to the U133 Plus 2.0 (Genechip, Affymetrix),
washing, and scanning were performed according to the
manufacturer’s protocol. Washing and staining were performed
using the Affymetrix GeneChip Fluidic Station 450. Probe arrays
were scanned using Affymetrix GeneChip Scanner 3000 G7.
Statistical analysis was performed using the method of robust
multiarray analysis (RMA) described by Irizarry et al. (2003). To
identify differentially expressed genes, gene expression intensity
was compared using a moderated t-test and a Bayes smoothing
approach developed for a low number of replicates (Smyth, 2004).
To correct for the effect of multiple testing, the false discovery rate
was estimated from P values derived from the moderated t-test
statistics (Benjamini et al., 2001). The analysis was performed using
the affylmGUI graphical user interface for the limma microarray
package (Wettenhall et al., 2006).
KEGG and BioCarta analysis
Differentially expressed genes were analyzed according to
predeﬁned pathways annotated by KEGG (Kyoto Encyclopedia
of Genes and Genomes; http://www.genome.ad.jp/kegg; Kanehisa
and Goto, 2000) and BioCarta (BioCarta Pathways [http://
www.biocarta.com/genes/allPathways.asp]) using the Gene Set
Analysis Toolkit. To determine whether the proportion of the
genes falling into each category (down- and up-regulated) was
statistically signiﬁcant, a hypergeometric test was applied (cutoff
P-value of 0.01). It should be noted that, in general, one gene
can participate in more than one KEGG or BioCarta pathway.
miRNAs expression proﬁling using the TaqMan1 human
microRNA array
Total cellular RNA and miRNAs were isolated from MG63 and
3AB-OS cells using the miRNeasy Mini Kit (Qiagen) and quantiﬁed
using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).
Total RNA (600 ng) was reverse-transcribed using MegaplexTM
RT Primers Human Pool A (Applied Biosystems, Foster City, CA)
according to the manufacturer’s instructions. The cDNA obtained
was loaded onto TaqMan1 Human MicroRNA Array A (Applied
Biosystems) according to the manufacturer’s protocols, and
then run on an ABI-PRISM 7900 HT Sequence Detection System
(Applied Biosystems). Data were quantiﬁed using the SDS 2.1
software and normalized using MammU6 as endogenous control.
The 2DDCt method was used to calculate the relative changes in
gene expression (Livak and Schmittgen, 2001).
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Predictive miRNAs for predictive target genes
The predictive miRNA targets were determined by using ﬁve
databases (TargetScan 5.1, MiRanda, PICTAR, miRbase, and
DIANA-microT databases) and applying the following criteria:
(i) the selected miRNAs must be predicted by at least two of the
ﬁve databases employed; (ii) considering the levels of expression of
both miRNAs and mRNA targets, for given Xg, the analysis must
select only those miRNAs satisfying:
jXm þ Xgj
jegj
< 1
where jj is the absolute value function. Given that eg¼Xg/2,
the above reads:
jXm þ Xgj
jXgj
<
1
2
we denoted Xm and Xg as miRNAs and gene expression values,
respectively.
The relationships between miRNA/mRNA expression proﬁles
were determined by evaluating Pearson’s correlation coefﬁcient
(r). This coefﬁcient, for continuous (interval level) data, ranges
from1 toþ1. A correlation>0.8 is generally described as strong,
whereas a correlation <0.5 is described as weak.
Quantitative real-time PCR
Real-time PCR mixtures were prepared as previously described
(Federico et al., 2010). Quantitative real-time PCR (qPCR) was
performed using the primers (Proligo, Milan, Italy) provided in
Table 1, and qPCRdatawere analyzed by SDS2.1 software. Relative
transcript levels were determined using the 2DDCt method (Livak
and Schmittgen, 2001) and normalized to GAPDH.
Western blot analysis
Cells were washed in PBS and incubated in ice-cold lysis buffer
(RIPA buffer 50ml/106 cells) containing protease inhibitor cocktail
(Sigma–Aldrich Srl) for 30min and then sonicated three times for
10 sec. Equivalent amounts of proteins (40mg) were separated by
SDS–polyacrylamide gel electrophoresis and transferred to a
nitrocellulose membrane (Bio-Rad Laboratories Srl, Segrate (MI),
Italy) for detection with primary antibodies against CCND2, GHR,
HMGA2, IGF2, MEST (Peg1), MSTN (GDF8; diluted 1:300;
Santa Cruz Biotechnology, Santa Cruz, CA), and Lin28B (diluted
1:100; Abcam, Cambridge, UK) and the appropriate horseradish
peroxidase-conjugated secondary antibodies. Immunoreactive
signals were detected using enhanced chemiluminescence (ECL)
reagents (Bio-Rad). The correct protein loading was conﬁrmed
by stripping the immunoblot and reprobing with primary antibody
for actin (diluted 1:500; Sigma–Aldrich Srl). Quantiﬁcation was
performed using Quantity One software, and the data (relative
density normalized to actin) were expressed as mean SD of four
experiments.
Statistical analysis
Data, represented as mean SD, were analyzed using the two-
tailed Student’s t-test.
Results
Karyotyping 3AB-OS CSCs
The human osteosarcoma cell line MG63, from which 3AB-OS
CSCs were produced, has a complex karyotype with a
chromosome number ranging from 61 to 66 (hypotriploid
karyotype), with chromosome translocations and gains/losses
in genomic sequences, accompanied by trisomies of numerous
chromosomes, nullisomy of chromosome 9 and 18–19 marker
chromosomes (Lim et al., 2004).
In this study, we assessed the ploidy of 3AB-OS cells byQFQ
banding chromosome analysis. The analysis of 22 metaphase
spreads showed that the 3AB-OS karyotype is a hypertriploid
composite (cp), with great heterogeneity and a modal number
of chromosomes ranging from71 to 82. Themain and recurrent
chromosome abnormalities were: trisomies for chromosomes
1, 4, 11, 16, 18, and 20; monosomy for chromosome 19;
nullisomy for chromosomes 9 and Y; a number of
supernumerary marker chromosomes ranging from 31 to 35;
derivative of chromosome9; andother chromosome structural
abnormalities. The ISCN karyotype was deﬁned as follows: 71–
82, X,Y,þ1,þ4,9,9, der(9),þ11,þ16,þ18,19,þ20,
þ31–35mar[cp22]. Figure 1A shows an aneuploid karyotype
with 78 chromosomes and the following characteristics:
trisomies of chromosomes 1, 4, 11, 16, 18, and 20; monosomies
of chromosomes 3 and 22; nullisomies of chromosomes 9, 19,
andY; derivative of chromosome 9 (mar); and 32 unidentiﬁable
marker chromosomes. In Figure 1B, ﬂow-cytometric analysis
shows aDNA index of 1.70 (triploid cells) forMG63 cells and of
2.1 (tetraploid cells) for 3AB-OS cells.
Array CGH analysis
To detect unbalanced chromosomal changes in 3AB-OS cells,
we performed array CGH analysis in comparison with
MG63 cells. Figure 1C describes the proﬁles of individual
chromosomes. Table 2 presents the CNV type (loss/gain), the
involved chromosome (Chr), the map positions (start/end bp),
the chromosomal band (start/end chr band), and the size of
chromosomal aberration (Mb), according to the International
Human Genome Consortium (build36; March 2006; hg18).
Overall, as indicated in both Figure 1C and Table 2, most of the
chromosomes had aberrations ranging from 0.9 to 116Mb.
In particular, we identiﬁed 49 CNVs (22 gains and 27 losses)
distributed among most of the chromosomes, with
homozygous losses detected in chromosomes 4, 6, 8, and 9.
Centrosome, multipolar spindles, and
nuclei number analyses
During mitosis, centrosomes direct the formation of bipolar
mitotic spindles that ensure equal segregation of chromosomes
between daughter cells. Loss of centrosome homeostasis
induces centrosome ampliﬁcation, aberrant mitosis, and
TABLE 1. Primers used for real-time RT-PCR analysis
Gene Forward primer 50–30 Reverse primer 50–30
CCND2 TCACCAACACAGACGTGGA TGTAGGGGTGCTGGCTTG
GHR CCAGTTTCCATGGTTCTTAATTAT TTCCTTTAATCTTTGGAACTGG
HMGA2 CGAAAGGTGCTGGGCAGCTCCGG CCATTTCCTAGGTCTGCCTCTTG
IGF2 CCTCCAGTTCGTCTGTGGG CACGTCCCTCTCGGACTTG
LIN28B CCTGTTTAGGAAGTGAAAGAAGAC CACTTCTTTGGCTGAGGAGGTAG
MEST/PEG1 CCTGTAGGCAAGGTCTTACCTG GAAGACTTCCATGAGTGAAGGGC
MSTN TGGTCATGATCTTGCTGTAACCTT TGTCTGTTACCTTGACCTCTAAAA
GAPDH TTCGACAGTCAGCCGCATCTTCTT GCCCAATACGACCAAATCCGTTGA
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altered chromosomes (Fukasawa, 2005). In
Figure 2A, ﬂuorescence microscopy (a) shows the
centrosomes, while diagram (b) indicates the percentage of
cells with abnormal centrosome number (>2). Only a few
supernumerary centrosomes (3.7%) were found in HS68 cells,
while the percentage of these chromosomes was 16.3% in
MG63 cells and 32.5% in 3AB-OS cells. Figure 2Ba,b shows that
there were no atypical mitotic spindles in HS68, but that 20.4%
of MG63 cells and 32.8% of 3AB-OS cells exhibited multipolar
mitotic spindles. Figure 2C shows that bothMG63 and 3AB-OS
cells exhibited bi-and multinucleation, in contrast to HS68 cells
with no abnormal nuclei. In 3AB-OS cells, the percentage of
binucleated (BN, 3.5%) andmultinucleated (MN, 6.9%) cells was
much greater than in MG63 cells (BN, 1.3%; MN, 1.0%). In
addition, 3AB-OS cells exhibited numerous multinucleated
giant cells (c), which were not found in MG63 cells.
Figure 2C also shows, in both MG63 and 3AB-OS cells, the
presence of micronuclei (mn), which were more prevalent in
3AB-OS cells (data not shown).
Transcriptome analysis of 3AB-OS cancer stem cells
Affymetrix microarray analysis was performed to identify
differentially expressed genes (DEGs) in 3AB-OS cells with
respect to MG63 cells. To represent the full list of DEGs
(Supplementary Table 1), we generated a heat map by
hierarchical clustering, as implemented in GeneSpring GX
(Fig. 3A), which grouped 3,512 DEGs of which 1,632 were up-
regulated (fold change 1) and 1,880 down-regulated (fold
change1).We applied to the 3,512 DEGs the bioinformatic
resources KEGG and BioCarta. KEGG analysis classiﬁed 518
genes of which 335 were from the down-regulated list and 183
from the up-regulated list, while BioCarta analysis classiﬁed 130
genes of which 73 were from the down-regulated list and 57
from the up-regulated list. A full list of the identiﬁed pathways,
ranked by a hypergeometric test P-value (up-/down-regulated
pathways), is shown in Figure 3B.
To select the pathways correlated with the most important
processes that characterize carcinogenesis and stemness, we
integrated the KEGG and BioCarta data. Figure 4 presents the
162 up-/down-regulated genes involved in the following
pathways: WNT signaling (31 genes; P-value¼ 4.71E04);
Notch signaling (seven genes; P-value¼ 6.76E03); Hedgehog
signaling (eight genes; P-value¼ 1.90E03); ABC transporters
general (11 genes; P-value¼ 3.57E03); MAPK signaling (47
genes; P-value¼ 2.16E03); cell cycle regulators (14 genes; P-
value¼ 3.72E03); apoptosis (24 genes; P-value¼ 3.88E05);
ECM-receptor interaction and cell communication (36 genes;
P-value¼ 5.52E05); and cell adhesion molecules (17 genes;
P-value¼ 2.95E03). Figure 4 also illustrates 34 genes either
highly up-regulated (14 genes, fold change 6.3; P-value¼
2.05E05) or strongly down-regulated (20 genes, fold change
6.3; P-value¼ 2.48E05), most of which were not
attributable to speciﬁc pathways.
MicroRNA expression in MG63 and in 3AB-OS cells
Here, we analyzed the miRNAs present in MG63 and 3AB-OS
cells. We identiﬁed 189 miRNAs of which 152 differentially
expressed in the two cell lines (Fig. 5A) and 37 termed
Fig. 1. Cytogenetics andDNAploidy. A:Typicalmetaphase analysis of 3AB-OS cells. B: Ploidy pattern in human osteosarcomaMG63 and 3AB-
OScells.Normalhuman lymphocyteswereusedasadiploid control.Thedatarepresent themeanwithstandarddeviation (nU 4).MP<0.01; t-test.
C:WholegenomeaCGHproﬁlesof3AB-OScells.X-axisrepresents individual chromosomesandY-axis represents thesignal intensity in log2ratio
(3AB-OS/MG63). Green dots represent the probes above ratio zero and red dots those below ratio zero. The analytical method applied was the
robust binary segmentation (P-value: 0.001; min clones: 5; min Mbp: 0.1; threshold: 0.1).
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‘‘3AB-OS-only’’ expressed only in 3AB-OS cells (Table 3).
Overall, 3AB-OS cells showed, with respect to MG63 cells, 54
up-regulated miRNAs with relative quantiﬁcation (RQ) 1, 98
down-regulated miRNAs with RQ 1, and 37 ‘‘3AB-OS-
only’’ miRNAs, for which RQ could not be calculated as they
were not measurable in MG63 cells.
To determine which of the 189 identiﬁed miRNAs may be
predictively involved in the control of the 196 selected genes,
we performed an analysis employing ﬁve integrated databases
(Supplementary Table 2). Based on this analysis, we selected 46
miRNAs, which included 9 up-regulated, 10 ‘‘3AB-OS-only,’’
and 27 down-regulated (Table 4). The results of this integrated
analysis also permitted the evaluation of the number and
percentage of genes present in predictably functional pathways
(Table 5). The results show that, excluding Notch and
Hedgehog signaling, and ABC transporter general pathways, all
other pathways have a percentage of targeted genes >30%,
suggesting that those genes could be strongly controlled by the
miRNAs identiﬁed. Integration of miRNAs and anticorrelated
genes yielded evidence, by Pearson’s correlation coefﬁcient
analysis (r¼0.96), of a strong inverse linear correlation
(Fig. 5B). As reported in Supplementary Table 3, the 46miRNAs
appeared to regulate the expression of 78 of the 196 selected
genes, and 23 of them seemed to be under the control of ‘‘3AB-
OS-only’’ miRNAs. Supplementary Table 3 also shows that,
among the down-regulated miRNAs, those with the most
predictive target genes are the miRNAs families let 7/98 (15
target genes) and 29a,b,c (7 target genes). Thus, based on these
analyses, we selected from the list presented in Supplementary
Table 3 the members of the miRNA families with their most
strongly up-regulated predictive genes. Table 6 lists the
members of the let-7/98 family (mean fold change 4.9) that
appear to be anti-correlated with HMGA2 (high mobility group
AT-hook 2; fold change þ6.7), Lin28B (Lin-28 homolog B; fold
change þ6.9), CCND2 (cyclin D2; fold change þ8.1), MEST
(mesoderm-speciﬁc transcript; fold change þ6.3) and GHR
(growth hormone receptor; fold changeþ5.0) genes; this table
also gives the members of the miR-29a,b,c family (mean fold
change4.6) that appear to be anti-correlated with the MSTN
(myostatin; fold change þ8.6), CCND2 and MEST genes. Even
though our analysis indicated that IGF2 (insulin-like growth
factor 2; fold change þ7.1) did not appear to be under
the control of identiﬁed miRNAs, it is also enclosed in
Supplementary Table 1, as it could be strongly inﬂuenced by
Lin28B (Lu et al., 2009).
To test whether expression differences evaluated by
microarray analysis were reproducible for this subset of genes,
we performed quantitative real-time PCR (q-PCR) with
independently collected RNA samples. The results (Fig. 5C)
were in agreement with the microarray analysis. To evaluate
whether these mRNAs were translated, we then measured the
expression levels of these genes by Western blot analysis
(Fig. 5D), showing that the levels of the corresponding proteins
(Fig. 5E) were higher in 3AB-OS than inMG63 cells (fold change
ranging from 1.4 to 2.8).
Discussion
Most highly malignant cells have an abnormal number of
chromosomes characterized by changes in structure, with their
karyotypic complexity being associated with aggressive clinical
behavior and poor prognosis (Roschke and Kirsch, 2010). Since
tumors with a poor outcome have been associated with CSC
presence, the number of papers describing CSCs has markedly
increased (McCubrey et al., 2012). Nevertheless, until now,
genetic and molecular characterization of CSCs has been little
explored.
Previously, we have reported for the ﬁrst time the isolation
of a humanosteosarcoma cancer stem cell line (3AB-OS). Here,
we characterized the 3AB-OS cell line at genetic and molecular
level, and to our knowledge, this is the ﬁrst CSC line to be
characterized.
We found that 3AB-OS cells have a signiﬁcant chromosomal
complexity and a large number of molecular abnormalities,
which are characteristic of the most aggressive human cancers.
Compared to parental MG63 cells, which have a hypotriploid
karyotype and chromosome number ranging from 61 to 66,
3AB-OS cells had a hypertriploid karyotype and chromosome
number ranging from 71 to 82. 3AB-OS cells also showed
monosomies, trisomies and nullisomies, together with 32
unidentiﬁable marker chromosomes, and they exhibited 49
CNVs (gains/losses), spanning almost all the chromosomes.
Remarkably, the abnormalities evidenced in 3AB-OS cells
appear to be strongly congruent with abnormalities described
in the literature in a large number of pediatric and adult
osteosarcomas (Bridge et al., 1997; Batanian et al., 2002; Niini
et al., 2011), which have shown a karyotype ranging from
haploid to near hexaploid, with structural abnormalities
involving the chromosomal regions 1p11–13, 4q27–33, 6p23–
25, 6q16–25, 7q11–36, 11p10–15, 11q23, and 17p11.2–13.
Moreover, 3AB-OS cells showed losses/gains in agreement
TABLE 2. Array CGH analysis of 3AB-OS cells DNA (testing) compared
with MG63 cells DNA (reference)
CNV
type Chr Start (bp) End (bp)
Start
(chr band)
End
(chr band)
Size
(Mb)
Loss 1 60,900,000 84,900,000 1p31.3 1p22.3 24
Loss 1 95,800,000 113,300,000 1p21.3 1p13.2 17.5
Loss 2 100,000 13,300,000 2p25.3 2p24.3 13.2
Gain 2 17,700,000 32,400,002 2p24.2 2p22.3 14.7
Loss 2 94,900,000 156,900,000 2q11.1 2q24.1 62
Loss 3 95,500,000 162,100,000 3q11.2 3q26.1 66.6
Gain 4 100,000 34,500,000 4p16.3 4p15.1 34.4
2X Loss 4 42,468,752 43,427,148 4p13 4p13 0.9
2X Loss 4 52,627,772 54,544,572 4q12 4q12 1.9
2X Loss 4 158,700,000 165,400,000 4q32.1 4q32.3 6.7
2X Loss 4 188,600,000 190,600,000 4q35.2 4q35.2 2
Loss 4 176,069,488 180,478,112 4q34.1 4q34.3 4.4
Loss 5 84,300,000 122,600,000 5q14.3 5q23.2 38.3
Loss 5 176,800,000 178,200,000 5q35.3 5q35.3 1.4
Loss 6 2,500,000 14,200,000 6p25.2 6p23 11.7
Gain 6 15,600,000 32,200,000 6p22.3 6p21.32 16.6
2X Loss 6 33,000,000 35,400,000 6p21.32 6p21.31 2.4
Gain 6 39,800,000 44,000,000 6p21.2 6p21.1 4.2
Gain 6 45,500,000 47,400,000 6p12.3 6p12.3 1.9
Gain 6 52,800,000 71,600,000 6p12.1 6q13 18.8
Gain 6 152,100,000 170,600,000 6q25.1 6q27 18.5
Loss 6 44,110,044 45,480,124 6p21.1 6p12.3 1.4
Gain 7 65,300,004 143,200,000 7q11.21 7q35 77.9
Loss 8 900,000 107,900,000 8p23.3 8q23.1 107
2X Loss 8 109,600,000 113,300,000 8q23.1 8q23.3 3.7
Gain 8 116,500,000 117,700,000 8q23.3 8q23.3 1.2
Gain 8 120,400,000 126,500,000 8q24.12 8q24.13 6.1
2X Loss 8 132,100,008 144,600,000 8q24.22 8q24.3 12.5
Loss 9 300,000 2,700,000 9p24.3 9p24.2 2.4
2X Loss 9 12,600,000 16,200,001 9p23 9p22.3 3.6
Loss 9 18,100,000 20,300,000 9p22.2 9p21.3 2.2
Gain 9 21,900,000 31,700,000 9p21.3 9p21.1 9.8
Gain 10 51,200,000 78,700,000 10q11.23 10q22.3 27.5
Gain 10 99,700,000 130,899,992 10q24.2 10q26.3 31.2
Gain 11 18,200,000 134,300,000 11p15.1 11q25 116.1
Gain 12 1,900,000 25,000,000 12p13.33 12p12.1 23.1
Loss 13 18,500,000 114,100,000 13q12.11 13q34 95.6
Gain 14 21,200,000 60,400,000 14q11.2 14q23.1 39.2
Gain 14 65,600,000 106,200,000 14q23.3 14q32.33 40.6
Gain 15 19,500,000 40,900,000 15q11.2 15q15.2 21.4
Loss 15 44,100,000 64,400,000 15q21.1 15q22.31 20.3
Loss 16 100,000 29,100,000 16p13.3 16p11.2 29
Loss 16 50,000,000 58,300,000 16q12.1 16q21 8.3
Gain 16 59,300,000 83,600,000 16q21 16q24.1 24.3
Gain 17 12,500,000 17,000,000 17p12 17p11.2 4.5
Gain 18 200,000 76,000,000 18p11.32 18q23 75.8
Loss 20 7,700,000 10,000,000 20p12.3 20p12.2 2.3
Gain 20 14,500,000 60,900,000 20p12.1 20q13.33 46.4
Loss X 300,000 26,900,000 Xp22.33 Xp21.3 26.6
JOURNAL OF CELLULAR PHYSIOLOGY
1194 D I F I O R E E T A L .
Fig. 2. Immunoﬂuorescencemicroscopy analysis of centrosomes,mitotic spindles, andnuclei inHS68 (control ﬁbroblasts),MG63, and 3AB-OS
cells. Aa: Centrosomes were detected by the presence of g-tubulin (green) and nuclei by DAPI (blue). Ab: Graph summarizing centrosome
aberration frequency. Ba: Multipolar spindles were detected by the presence of g-tubulin (green) and b-tubulin (red); nuclei by DAPI (blue). Bb:
Graphsummarizingaberrant spindlepercentages (‡3).Ca:Binucleated (BN)andmultinucleated (MN)cellsdetectedbythepresenceofb-tubulin
(red) and DAPI (blue). Arrows indicate micronuclei (mn). Cb: Graph summarizing the percentage of binucleate and multinucleate cells.
Cc: multinucleated giant cell detected by DAPI (blue). The data represent the mean with standard deviation (nU 4). MP<0.05 and MMP<0.005;
t-test. Original magniﬁcation, 400T.
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with those seen in osteosarcoma patients (Bridge et al., 1997;
Batanian et al., 2002; Niini et al., 2011), such as losses at
chromosome arms 8p, 9p, 16p, 3q, 13q, and gains at
chromosome arms 6p, 8q, 12p, 14q, 17p, and 20q.
It is known that karyotypic complexity is reﬂected in
aneuploidy (chromosomal instability), which is believed to be
a driving force for tumorigenesis (Roschke and Kirsch, 2010).
Even if the origin of chromosomal instability is not clear, defects
in both centrosome duplication and mitotic spindle checkpoint
can be considered early features in tumor initiation and
progression (Chan, 2011). Our results show that both MG63
and 3AB-OS cells have abnormal centrosome number,
multipolar spindles, and bi- and multinucleation. In 3AB-OS
cells, these abnormalities appeared to be much higher than in
MG63 cells, and they included a number of giant multinucleated
cells, not evidenced in MG63 cells. Highly aneuploid cells
have varied activation of pro-proliferative pathways with
dysfunctions in cyclins, pRb, and E2F family transcription
Fig. 3. Transcriptomeanalysis.A:Hierarchical clusteringanalysis of theexpressiondataofMG63and3AB-OScell lines (cut-offP-valueof0.001).
Each row represents a separate element on the microarray, and each column represents a cell line. In the heat map, the log scale of absolute
expressionvaluesofbothcell linesarerepresentedbycolors: greensquaresrepresent low-expressedgenes, redsquaresrepresenthigh-expressed
genes. B: Enrichment analysis for KEGG and BioCarta pathways. The bar chart shows the number of genes in the canonical KEGG or BioCarta
pathwaysseparatelyfordown-regulated(green)andup-regulated(red)transcripts.Foranover-representedKEGGorBioCartapathway,acut-off
P-value of 0.01 was selected. Indices for KEGG and BioCarta terms are reported in Supplementary Figure 1.
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factors, which could be crucial in centrosome ampliﬁcation and
chromosome instability (Mayhew et al., 2007). Similar
dysfunctions have also been reported in osteosarcoma patients,
where array CGH revealed frequent alterations of G1/S
checkpoint genes (Niini et al., 2011).Wehave previously shown
(De Blasio et al., 2005) that, with respect to MG63 cells, 3AB-
OS cells express much higher levels of hyperphosphorylated
pRb, known to inﬂuence the timing of G1/S, and that this was
accompanied by substantial increases in the levels of molecular
partners contributing to G1/S and G2/M transition (Di Fiore
et al., 2009). Now, we suggest a link between the altered
gene expressions previously reported in 3AB-OS cells and
the centrosome ampliﬁcation and aneuploidy described here.
We report here the gene expression proﬁle of 3AB-OS cells
in comparison with MG63 cells and, employing KEGG and
BioCarta analysis, we selected 196 up-/down-regulated
genes spanning important regulatory pathways involved in
tumorigenesis and stemness (WNT, Notch and Hedgehog
signaling; ABC transporters in general; MAPK signaling; cell
cycle regulators; apoptosis; ECM-receptor interaction and cell
Fig. 4. Hierarchical clusterings related topathways identiﬁedby the integratedanalysesusingKEGGandBioCartadatabases.Representationof
rows and columns is the same as reported in Figure 3. Also indicated are highly up-/down-regulated genes,most of which cannot be attributed to
speciﬁc pathways.
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communication; cell adhesion molecules), most of which have
been reported in osteosarcoma patients (Cleton-Jansen et al.,
2009).
It is known that miRNAs may act as oncogenes or tumor
suppressor genes (Iorio and Croce, 2009), and thus, they
constitute a large gene regulatory network that can modulate
proliferation, cancer, and stemness. This evidence raises the
intriguing idea to modulate microRNA expression as a possible
therapeutic approach to cancer. In this study, we demonstrated
the overexpression/underexpression of 189 miRNAs, of which
152 differentially expressed in 3AB-OS and MG63 cells and
where 37 expressed in 3AB-OS cells only. We submitted the
selected genes to a predictive integrated analysis using ﬁve
databases, and we selected 46 miRNAs with their predicted
gene targets involved in pathways including apoptosis, cell cycle,
Wnt, and MAPK. Interestingly, among these miRNAs, a large
number of both up-regulated (miR-329, miR-335, miR-376a,
miR-382, miR-409-5p, miR-127-3p, miR-376a, miR-376c, miR-
493, miR-495, miR-654-3p, miR-299-5p, miR-410, and miR-
223) and down-regulated (miR-10b, miR-195, let-7g, miR-16-2,
miR-519d, miR-26b, miR-16, and miR-29b) coincide with those
identiﬁed in osteosarcoma patients (Maire et al., 2011; Jones
et al., 2012). Thus, studying 3AB-OS CSCs will permit the
identiﬁcation of new molecular pathways that could be
Fig. 5. miRNAs, q-real-time PCR, Western blot analyses, and
miRNAs/antiregulated genes. A: Clustering of 152 differentially
expressed miRNAs. Each row represents a separate element on the
array, and each column represents a cell line. The scale (0.0–16.2)
indicates the DCt values represented by colors. Green squares
represent up-regulation, and red squares represent down-regulation.
B: Integrated analysis of miRNA and mRNA expression proﬁles. X-
axis (independent variable) represents the miRNA expression signal
intensity ratio (3AB-OS/MG63) in log2 scale and Y-axis (dependent
variable) represents the mRNA expression signal intensity ratio
(3AB-OS/MG63) in log2 scale. Pearson’s r-value indicates the
correlation coefﬁcient. C: qPCRwith independently collectedmRNA
samples. Relative transcript levels were determined using the 2DDCt
method and normalized to GAPDH. The data represent the mean
with standard deviation (nU 4). MMP<0.001; t-test. D: Western blot
analysis. E: Quantiﬁcation of protein bands by densitometric analysis.
The data (relative density normalized to actin) represent the mean
with standard deviation (nU 4). MP<0.05; t-test.
TABLE 3. ‘‘3AB-OS-only’’ miRNAs
hsa-miR-133a
hsa-miR-501-3p
hsa-miR-654-5p
hsa-miR-493
hsa-miR-129-3p
hsa-miR-299-5p
hsa-miR-409-5p
hsa-miR-499-5p
hsa-miR-1
hsa-miR-519a
hsa-miR-375
hsa-miR-188-3p
hsa-miR-146b-3p
hsa-miR-541
hsa-miR-122
hsa-miR-517a
hsa-miR-338-3p
hsa-miR-369-5p
hsa-miR-519d
hsa-miR-491-3p
hsa-miR-329
hsa-miR-654-3p
hsa-miR-429
hsa-miR-127-5p
hsa-miR-548b-5p
hsa-miR-412
hsa-miR-506
hsa-miR-380
hsa-miR-517c
hsa-miR-376b
hsa-miR-511
hsa-miR-367
hsa-miR-302c
hsa-miR-369-3p
hsa-miR-891a
hsa-miR-136
hsa-miR-299-3p
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responsible for the stemness character of human
osteosarcoma.
In our study, among the predicted miRNA–mRNA
interactions, the most intriguing seemed to be those involving
the down-regulated miR let-7/98 and 29a,b,c families and the
up-regulated MSTN, CCND2, Lin28B, MEST, HMGA2, and
GHR genes. These players, described in Figure 6 together with
IGF-2, captured our attention for a large number of reasons: (1)
both let-7/98 and 29a,b,c miRNAs serve as strong tumor
suppressors by targeting genes that inﬂuence cell-cycle
progression and apoptosis, and are strongly down-regulated in
several types of cancers, thus favoring tumor progression
(Fabbri et al., 2007; Bussing et al., 2008); (2) processing of the
let-7 family is blocked by Lin28B, an RNA-binding protein that
when overexpressed is considered an unfavorable prognostic
marker in various cancer types (Viswanathan et al., 2009);
(3) let-7/98 and Lin-28 form an autoregulatory circuit that
controls miRNA processing (Rybak et al., 2008) and which
is fundamental for maintaining stemness; (4) Lin28B
overexpression also enhances the expression of HMGA2, an
oncogene, that is, one of the major let-7/98 targets; HMGA2 is
undetectable in normal adult tissues, but is widely expressed in
undifferentiated embryonic tissues and cancer cells (Boyerinas
et al., 2008); (5) Lin28B may also up-regulate the expression of
IGF-2 (Lu et al., 2009), a normally imprinted oncogene whose
loss of imprinting (LOI) has been associatedwith increased risks
of a number of cancers, including pediatric osteosarcoma (Li
et al., 2009); (6) let7/98 may also regulate GHR, an oncogene
that activates survival and antiapoptotic pathways and that is up-
regulated in a large number of cancers (Bidosee et al., 2011);
(7) let-7/98 miR family also targets CCND2, an oncogene that
regulates cell-cycle progression and that is overexpressed in
various cancer types, including osteosarcoma (Sarkar et al.,
2010); (8) CCND2 is also under the control of miR-29a,b,c
members that strongly control theMSTN andMEST genes, two
particularly interesting genes because MSTN promotes human
embryonic stem cell self-renewal and potently increases in
cancer cachexia (Hannan et al., 2009; BennyKlimek et al., 2010),
while MEST is an imprinted gene whose LOI has been reported
in pediatric osteosarcoma and in many other cancer types
(Li et al., 2008).
The scenario described and discussed in Figure 6 suggests
that the down-regulation of miR let-7/98 and miR 29a,b,c may
be the cause of the up-regulation of the reported genes and
highlights for the ﬁrst time a regulatory network between each
of them, which could be characteristic of the subpopulation of
CSCs that drives tumorigenesis and chemoresistance in
osteosarcoma. The ﬁndings strongly support the idea that these
cells may be a valuable model for studying the origin and
aggressiveness of osteosarcoma to ﬁnd ways of targeting its
aggressive behavior.
Currently, we are developing a new research project aimed
at the functional validation of miR let-7d and miR-29b-1, and to
establish their role in maintaining the stemness properties of
3AB-OS cells.
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